CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
NCT03002805 is a phase 1 interventional trial sponsored by CBA Research. As of 21 Nov 2026, it has a status the registry marks as unknown. It studies CBT-1® in Sarcoma. The registry lists an enrollment of 46 participants at 6 sites in 1 country. The registry lists a start date of 29 Mar 2018 and a primary completion date of 30 Sept 2020. 2 of its registered investigators have a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03002805 |
| Status | Unknown |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | CBA Research |
| Enrollment | 46 |
| Registered sites | 6 |
| Countries | 1 |
| Conditions | Sarcoma |
| Drugs | CBT-1® |
| Start | 29 Mar 2018 |
| Primary completion | 30 Sept 2020 |
| Study completion | 30 Sept 2020 |
| Last update posted | 19 Aug 2019 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sarcoma Oncology Research Center
Santa Monica
Sant P. Chawla, M.D.Recruiting
- Mayo Clinic
Jacksonville
Steven Attia, D.O.Recruiting
- Dana Farber Cancer Institute
Boston
Katherine Thornton, M.D.Recruiting - Massachusetts General Hospital
Boston
Gregory Cote, M.D., Ph.D.Recruiting
- University of Pittsburgh Medical Center
Pittsburgh
Melissa Burgess, M.D.Recruiting
- Seattle Cancer Care Alliance
Seattle
Lee Cranmer, M.D.Recruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03002805
Each answer restates registry values shown on this page.
What is NCT03002805?
NCT03002805 is a phase 1 interventional trial sponsored by CBA Research. It studies CBT-1® in Sarcoma.
Where does NCT03002805 run?
The registry lists 6 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03002805 study?
The registered drug and biological interventions are CBT-1®.
When is NCT03002805 expected to complete?
The registry lists a primary completion date of 30 Sept 2020 and a study completion date of 30 Sept 2020. The sponsor last updated the record on 19 Aug 2019.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.